392 related articles for article (PubMed ID: 20002026)
1. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
[TBL] [Abstract][Full Text] [Related]
3. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
[TBL] [Abstract][Full Text] [Related]
4. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
[TBL] [Abstract][Full Text] [Related]
6. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
7. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
8. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
[TBL] [Abstract][Full Text] [Related]
10. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
[TBL] [Abstract][Full Text] [Related]
12. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.
Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C
Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208
[TBL] [Abstract][Full Text] [Related]
13. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
Seiderer J; Göke B; Ochsenkühn T
Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
[TBL] [Abstract][Full Text] [Related]
14. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
[TBL] [Abstract][Full Text] [Related]
15. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
16. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
17. Safety of infliximab in 10 years of clinical practice.
O'Donnell S; Murphy S; Anwar MM; O'Sullivan M; Breslin N; O'Connor HJ; Ryan BM; O'Morain CA
Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):603-6. PubMed ID: 21602689
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
[TBL] [Abstract][Full Text] [Related]
19. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
Ricart E; Panaccione R; Loftus EV; Tremaine WJ; Sandborn WJ
Am J Gastroenterol; 2001 Mar; 96(3):722-9. PubMed ID: 11280541
[TBL] [Abstract][Full Text] [Related]
20. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
Pearce CB; Lawrance IC
J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]